{"id":61517,"date":"2018-05-30T11:56:20","date_gmt":"2018-05-30T09:56:20","guid":{"rendered":"https:\/\/neurodev-ng.u-bordeaux.fr\/j-baufreton-b-bessiere-et-al-inmovement-disorders\/"},"modified":"2018-05-30T11:56:20","modified_gmt":"2018-05-30T09:56:20","slug":"j-baufreton-b-bessiere-et-al-inmovement-disorders","status":"publish","type":"post","link":"https:\/\/www.bordeaux-neurocampus.fr\/en\/j-baufreton-b-bessiere-et-al-inmovement-disorders\/","title":{"rendered":"J. Baufreton, B. Bessi\u00e8re et al. in<em>Movement Disorders<\/em>"},"content":{"rendered":"<div class=\"innertube\">\n<p><em><a class=\"external\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29756234\"><strong>Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.<\/strong> <\/a>Baufreton J, Milekovic T, Li Q, McGuire S, Moraud EM, Porras G, Sun S, Ko WKD, Chazalon M, Morin S, Normand E, Farjot G, Milet A, Pype J, Pioli E, Courtine G, Bessi\u00e8re B, Bezard E. Mov Disord. 2018 May 14. doi: 10.1002\/mds.27404. [Epub ahead of print]<\/em><\/p>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_56617\" aria-describedby=\"caption-attachment-56617\" style=\"width: 300px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2018\/06\/Baufreton-Bessiere300p.jpg\" rel=\"lightbox[61517]\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-56617 size-medium\" src=\"https:\/\/www.bordeaux-neurocampus.fr\/wp-content\/uploads\/2018\/06\/Baufreton-Bessiere300p-300x164.jpg\" alt=\"J.Baufreton et B. Bessi\u00e8re\" width=\"300\" height=\"164\" \/><\/a><figcaption id=\"caption-attachment-56617\" class=\"wp-caption-text\">J.Baufreton (\u00e0 gauche) et B. Bessi\u00e8re (\u00e0 droite)<\/figcaption><\/figure>\n<p><em><a href=\"https:\/\/www.bordeaux-neurocampus.fr\/staff\/jerome-baufreton\/\"><strong>J\u00e9r\u00f4me Baufreton<\/strong><\/a> is co-directing the team \u201cDopamine &amp; Neuronal Assemblies\u201d at the CNRS UMR5293 unit, Institut des Maladies Neurod\u00e9g\u00e9n\u00e9ratives.<br \/>\n<\/em><br \/>\n<em><strong>Baptiste Bessi\u00e8re<\/strong> did his Ph.D CIFRE at the University of Bordeaux in the team \u201cHomeostasy, Allostasy Pathology Rehabilitation\u201d directed by the Pr Guy Simonnet in collaboration with Air Liquide. He is currently working at Air Liquide Healthcare as Clinical Development Project Manager<span class=\"image-wrapper frame\">.<br \/>\n<\/span><\/em><\/p>\n<hr \/>\n<p><strong>Xenon is noble gas which is known<\/strong> to freely diffuse across lipid membranes and interact with a great variety of protein complexes including NMDA receptors. Because Xenon acts as an antagonist of NMDA receptor, Baptiste Bessi\u00e8re got the original idea that this noble gas could be a good and safe antidyskinetic agent.<\/p>\n<p>In this study, we demonstrated that Xenon displays the same efficacy than amantadine (a non-selective antagonist of NMDA receptors which is the only antidyskinetic drug currently available on the market) in reducing L-DOPA-induced dyskinesia (LIDs) in both rodents and primate models of Parkinson\u2019s disease. We also unravel its mechanism of action by showing that Xenon by inhibiting striatal NMDA receptors normalizes maladaptive cortico-striatal plasticity.<\/p>\n<h2>Abstract<\/h2>\n<p><strong>Background:<\/strong> Parkinson\u2019s disease (PD) motor symptoms are treated with levodopa but long-term treatment leads to disabling dyskinesia. Altered synaptic transmission and maladaptive plasticity of corticostriatal glutamatergic projections play a critical role in dyskinesia pathophysiology.<\/p>\n<p><strong>Objectives:<\/strong> Since the noble gas xenon inhibits excitatory glutamatergic signalling primarily through allosteric antagonism of the NMDA receptors, we aimed at testing its putative antidyskinetic capabilities.<\/p>\n<p><strong>Results:<\/strong> Our study shows that xenon gas exposure (i) normalised synaptic transmission and reversed maladaptive plasticity of corticostriatal glutamatergic projections associated with levodopa-induced dyskinesia, (ii) ameliorated dyskinesia in rat and nonhuman primate models of PD and dyskinesia, and (iii) improved gait performance in a nonhuman primate model of PD.<\/p>\n<p><strong>Conclusions:<\/strong> These results pave the way for clinical testing of this believed safe, yet unconventional, approach.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<p class=\"content-contact\"><strong>Derni\u00e8re mise \u00e0 jour le 30.05.2018<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.<\/p>\n","protected":false},"author":108,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71],"tags":[],"class_list":["post-61517","post","type-post","status-publish","format-standard","hentry","category-highlight-en"],"_links":{"self":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts\/61517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/users\/108"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/comments?post=61517"}],"version-history":[{"count":0,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/posts\/61517\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/media?parent=61517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/categories?post=61517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bordeaux-neurocampus.fr\/en\/wp-json\/wp\/v2\/tags?post=61517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}